Simplex Trading
VYNE icon

Simplex Trading’s VYNE Therapeutics VYNE Stock Holding History

Simplex Trading’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44
Closed -$2K – 11558
2021
Q3 		$2K Buy
44
+11
+33% +$427 ﹤0.01% 9576
2021
Q2 		$2K Buy
33
+27
+450% +$2.14K ﹤0.01% 9755
2021
Q1 		$73K Buy
+6
New +$870 ﹤0.01% 6159

Other funds holding VYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Simplex Trading's VYNE Position: Q4 2022 in Review

Simplex Trading sold out of VYNE Therapeutics (VYNE) in Q4 2022, closing a stake of 1 share.

Simplex Trading first reported a position in VYNE in Q1 2021 and held it in 4 quarters. The position peaked at $49K in Q1 2021. 41 funds tracked by Wall St. Rank hold VYNE as of Q4 2022.

  • Simplex Trading reported no remaining VYNE Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Simplex Trading sold 1 VYNE Therapeutics share in Q4 2022.
  • Simplex Trading first reported a position in VYNE Therapeutics in Q1 2021 and held it in 4 quarters.
  • Simplex Trading's VYNE Therapeutics position peaked at $49K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2022.

Based on Simplex Trading's 13F filing for Q4 2022, filed 2 Feb 2023.